Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(01): 015-019
DOI: 10.4103/2278-330X.202557
ORIGINAL ARTICLE: Head and Neck Cancer

Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynx

Poonam Joshi
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Amit Joshi
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Vanita Norohna
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Pankaj Chaturvedi
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Vijay Patil
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Jai Prakash Agarwal
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Shashikant Juvekar
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
,
Kumar Prabhash
Department of Medical Oncology, Tata memorial Hospital, Mumbai, Maharashtra
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Bacground: To assess the response rate and impact of neoadjuvant chemotherapy (NACT) in advanced carcinoma of the hypopharynx and larynx. Materials and Methods: This is a retrospective case series of 80 patients with locally advanced laryngopharynx carcinoma who received NACT from April 2010 to October 2011 at our tertiary care center. The patients received NACT either for achieving resectability or for organ preservation. Results: Majority of the patients (60%) had T4 a disease. Grade 3 and 4 neutropenia was seen in 18%, febrile neutropenia in 4%, mucositis in 4%, diarrhea in 5%, and vomiting in 3% patients. Resectability could be achieved in 34%, and larynx was preserved in 51% patients at a mean follow-up of 13 months. Conclusions: NACT was safe with acceptable toxicity. Majority of the patients who achieved resectability had oropharyngeal involvement. NACT followed by concurrent chemoradiotherapy could provide a high rate of organ preservation.

Key words

Advanced carcinoma - hypopharynx - larynx - neoadjuvant chemotherapy


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Wolf GT, Hong WK, Fisher SG, Urba S, Endicott JW, Close L, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-90.
  • 2 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
  • 3 Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85:156-70.
  • 4 Hall SF, Groome PA, Irish J, O'Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: Establishing the baseline for hypopharyngeal carcinoma? Cancer 2009;115:5711-22.
  • 5 Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J, et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: Efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 2004;130:861-7.
  • 6 Horwitz SD, Caldarelli DD, Hendrickson FR. Treatment of carcinoma of the hypopharynx. Head Neck Surg 1979;2:107-11.
  • 7 Uzcudun AE, Bravo Fernández P, Sánchez JJ, García Grande A, Rabanal Retolaza I, González Barón M, et al. Clinical features of pharyngeal cancer: A retrospective study of 258 consecutive patients. J Laryngol Otol 2001;115:112-8.
  • 8 Keane TJ. Carcinoma of the hypopharynx. J Otolaryngol 1982;11:227-31.
  • 9 Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001;111:1079-87.
  • 10 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2012. Available from: http://www.seer.cancer.gov/csr/1975_2010. [Last accessed on 2015 Apr].
  • 11 Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: Pioneering new opportunities in head and neck oncology. Eur J Cancer 2003;39:560-71.
  • 12 Specenier PM, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited? Cancer Lett 2007;256:166-77.
  • 13 Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012;23:2708-14.
  • 14 Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101:142-52.
  • 15 Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.
  • 16 Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7.
  • 17 Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.